Clinical Trials Register

Summary
EudraCT Number:	2018-000518-39
Sponsor's Protocol Code Number:	CAIN457A2325
National Competent Authority:	Spain - AEMPS
Clinical Trial Type:	EEA CTA
Trial Status:	Completed
Date on which this record was first entered in the EudraCT database:	2019-01-22
Trial results	View results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

Spain - AEMPS

A.2

EudraCT number

2018-000518-39

A.3

Full title of the trial

Multicenter, rAndomized, double-blind, placebo-conTrolled, 52-week stUdy to demonstRatE the efficacy, safety and tolerability of subcutaneous secukinumab injections with 2 mL auto-injectors (300 mg) in adult subjects with moderate to severe plaque psoriasis

Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 52 semanas de duración para demostrar la eficacia, seguridad y tolerabilidad de inyecciones subcutáneas de secukinumab con autoinyectores de 2 ml (300 mg) en pacientes adultos con psoriasis en placas de moderada a grave

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

Study of efficacy and safety of secukinumab 2 mL auto-injector (300 mg) injections in subjects with moderate to severe plaque psoriasis.

Estudio de la eficacia y seguridad de un autoinyector de 2 ml de secukinumab (300 mg) en pacientes con psoriasis en placas de moderada a grave

A.3.2

Name or abbreviated title of the trial where available

MATURE

A.4.1

Sponsor's protocol code number

CAIN457A2325

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	Novartis Farmacéutica, S.A.
B.1.3.4	Country	Spain
B.3.1 and B.3.2	Status of the sponsor	Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	Novartis Pharma AG
B.4.2	Country	Switzerland
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	Novartis Farmacéutica, S.A.
B.5.2	Functional name of contact point	Trial Monitoring Organization (TMo)
B.5.3	Address:
B.5.3.1	Street Address	Gran Vía de les Corts Catalanes, 764
B.5.3.2	Town/ city	Barcelona
B.5.3.3	Post code	08013
B.5.3.4	Country	Spain
B.5.4	Telephone number	+34900353036
B.5.5	Fax number	+34932479903
B.5.6	E-mail	eecc.novartis@novartis.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	No
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Secukinumab
D.3.2	Product code	AIN457
D.3.4	Pharmaceutical form	Solution for injection in pre-filled pen
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	SECUKINUMAB
D.3.9.1	CAS number	1229022-83-6
D.3.9.2	Current sponsor code	AIN457
D.3.9.4	EV Substance Code	SUB33242
D.3.10	Strength
D.3.10.1	Concentration unit	mg/ml milligram(s)/millilitre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	150
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	No
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	Yes
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	Yes
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 2
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	COSENTYX
D.2.1.1.2	Name of the Marketing Authorisation holder	Novartis Europharm Limited
D.2.1.2	Country which granted the Marketing Authorisation	European Union
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	COSENTYX
D.3.2	Product code	AIN457
D.3.4	Pharmaceutical form	Solution for injection in pre-filled syringe
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	SECUKINUMAB
D.3.9.1	CAS number	1229022-83-6
D.3.9.2	Current sponsor code	AIN457
D.3.9.4	EV Substance Code	SUB33242
D.3.10	Strength
D.3.10.1	Concentration unit	mg/ml milligram(s)/millilitre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	150
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	No
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	Yes
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	Yes
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Solution for injection in pre-filled pen
D.8.4	Route of administration of the placebo	Subcutaneous use
D.8 Placebo: 2
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Solution for injection in pre-filled syringe
D.8.4	Route of administration of the placebo	Subcutaneous use

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

Moderate to severe plaque-type psoriasis

Psoriasis en placas de moderada a grave

E.1.1.1

Medical condition in easily understood language

Psoriasis looks like red, raised scaly areas of the skin

La psoriasis se ve como áreas escamosas y enrojecidas de la piel.

E.1.1.2

Therapeutic area

Diseases [C] - Skin and Connective Tissue Diseases [C17]

MedDRA Classification

E.1.2 Medical condition or disease under investigation

E.1.2	Version	20.0
E.1.2	Level	LLT
E.1.2	Classification code	10050576
E.1.2	Term	Psoriasis vulgaris
E.1.2	System Organ Class	100000004858

E.1.3

Condition being studied is a rare disease

E.2 Objective of the trial

E.2.1

Main objective of the trial

To demonstrate the efficacy of secukinumab 300 mg when administered in 2 mL auto-injector in subjects with plaque-type psoriasis with respect to both PASI 75 and IGA mod 2011 0 or 1 response (co-primary endpoint) at Week 12, compared to placebo.

Demostrar la eficacia de secukinumab 300 mg cuando se administra en autoinyector de 2 ml comparado con placebo en pacientes con psoriasis en placas con respecto a las respuestas del Índice de severidad y área de la psoriasis (PASI) 75 y respuesta 0 o 1 según la evaluación global del investigador modificada 2011 (IGA mod. 2011) (variables co-principales) en la semana 12.

E.2.2

Secondary objectives of the trial

To demonstrate efficacy of secukinumab 300 mg 2 mL AI in subjects with plaque-type psoriasis w.r.t. PASI 90 at Week 12, compared to placebo.
To assess efficacy of secukinumab 300 mg 2 mL AI in subjects with plaque-type psoriasis w.r.t. PASI score, IGA mod 2011 score, PASI 50/75/90/100 and IGA mod 2011 0 or 1 response up to Week 12 compared to placebo, and over time up to Week 52.
To investigate clinical safety and tolerability of secukinumab 300 mg 2 mL AI as assessed by vital signs, clinical laboratory variables, and AE monitoring, compared to placebo.
To assess subject usability (ability to follow instructions for use and potential use-related hazards) and satisfaction with the new secukinumab 2 mL AI utilizing a self-administered SIAQ and investigator/site staff observation of secukinumab 300 mg 2 mL AI administration.
To investigate effects of secukinumab 300 mg 2 mL AI w.r.t. DLQI 0 or 1 achievement and DLQI changes at Week 12 compared to placebo, and over time up to Week 52.

Demostrar la eficacia de secukinumab 300 mg cuando se administra en autoinyector de 2 ml comparado con placebo en pacientes con psoriasis en placas con respecto a la respuesta PASI 90 en la semana 12.
Evaluar la eficacia de secukinumab 300 mg cuando se administra en autoinyectores de 2 ml comparado con placebo en pacientes con psoriasis en placas con respecto a la puntuación PASI, la puntuación IGA mod. 2011, las respuestas PASI 50/75/90/100 y la respuesta IGA mod. 2011 0 o 1 hasta la semana 12 y a lo largo del tiempo hasta la semana 52.
Investigar la seguridad y tolerabilidad clínicas de secukinumab 300 mg en autoinyectores de 2 ml comparado con placebo evaluadas según las constantes vitales, variables clínicas de laboratorio y monitorización de acontecimientos adversos (AA).
Para otros objetivos ver protocolo

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

1. Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed. Where relevant, a legal representative will also sign the informed study consent according to local laws and regulations.
2. Men or women of at least 18 years of age at the time of Screening.
3. Chronic plaque-type psoriasis present for at least 6 months and diagnosed before Randomization.
4. Moderate to severe psoriasis as defined at Randomization by:
• PASI score of 12 or greater, and
• IGA mod 2011 score of 3 or greater (based on a scale of 0 – 4), and
• Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.
5. Candidate for systemic therapy.
This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by
• Topical treatment and/or
• Phototherapy and/or
• Previous systemic therapy

1. Los pacientes deben ser capaces de comprender y comunicarse con el investigador y cumplir los requisitos del estudio y deben presentar un consentimiento informado escrito, fechado y firmado antes de que se realice cualquier actividad relacionada con el estudio. Cuando proceda, un representante legal firmará también el consentimiento informado del estudio de acuerdo con la normativa y legislación locales.
2. Hombres o mujeres de al menos 18 años de edad en el momento de la selección.
3. Psoriasis crónica en placas existente durante al menos 6 meses y diagnosticada antes de la aleatorización.
4. Psoriasis de moderada a grave definida en la aleatorización basándose en:
• Puntuación PASI de 12 o superior y
• Puntuación IGA mod. 2011 de 3 o superior (basada en una escala de 0 – 4) y
• Área de superficie corporal (BSA) afectada por psoriasis en placas del 10 % o superior.
5. Candidato a tratamiento sistémico. El candidato a tratamiento sistémico se define como un paciente que tiene psoriasis crónica en placas de moderada a grave que se considera inadecuadamente controlada mediante
• Tratamiento tópico o
• Fototerapia o
• Tratamiento sistémico previo

E.4

Principal exclusion criteria

1. Forms of psoriasis other than chronic plaque-type at Screening or Randomization.
2. Drug-induced psoriasis at Randomization.
3. Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to. Subjects not willing to limit Ultraviolet (UV) light exposure during the course of the study will be considered not eligible for this study since UV light exposure is prohibited.
Note: administration of live vaccines 6 weeks prior to Randomization or during the study period is also prohibited.
4. Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the IL-17 receptor.
5. Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.
6. Pregnant or lactating women.
7. Women of child-bearing potential.
8. Active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis (PsA) that might confound the evaluation of the benefit of secukinumab therapy. Also, underlying conditions (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy. In addition, current severe progressive or uncontrolled diseases which renders the subject unsuitable for the trial or puts the subject at increased risk, including any medical or psychiatric condition which, in the Investigator’s opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
9. Presence of :
• Significant medical problems, including but not limited to the following: uncontrolled hypertension (repeated values of systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 95 mmHg), congestive heart failure (New York Heart Association status of class III or IV).
• Serum creatinine level exceeding 2.0 mg/dL (176.8 µmol/L).
• Total white blood cell (WBC) count < 2,500/µL, or platelets < 100,000/µL or neutrophils < 1,500/µL or hemoglobin < 8.5 g/dL at Screening.
10. Active systemic infections during the last two weeks (exception: common cold) prior to randomization or any infection that reoccurs on a regular basis.
11. History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis (TB) infection as defined by a positive central laboratory test result at screening. Subjects with a positive test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment must have been initiated and maintained according to local country guidelines prior to randomization.
12. Past medical history record or current infection with Human Immunodeficiency Virus, hepatitis B or hepatitis C prior to Randomization.
13. History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for Bowen’s disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
14. Inability or unwillingness to undergo repeated venipuncture (eg, because of poor tolerability or lack of access to veins) or to self-administer sub-cutaneous injections.
15. History or evidence of ongoing alcohol or drug abuse, within the last six months before Randomization.
16. History of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes.

1. Formas de psoriasis salvo psoriasis crónica en placas (p. ej., psoriasis pustulosa, eritrodérmica y gutata) en la selección o aleatorización.
2. Psoriasis provocada por fármacos (es decir nueva aparición o exacerbación actual por betabloqueantes, inhibidores de los canales de calcio o litio) en la aleatorización.
3. Uso actual de tratamientos prohibidos. Se deben cumplir los periodos de lavado descritos en el protocolo. Los pacientes que no deseen limitar la exposición a la luz ultravioleta (UV) (p. ej., tomar el sol o utilizar dispositivos de bronceado) durante el estudio no se considerarán elegibles para este estudio, ya que está prohibida la exposición a la luz UV.
Nota: también está prohibida la administración de vacunas vivas 6 semanas antes de la aleatorización o durante el estudio.
4. Exposición previa a secukinumab (AIN457) o a cualquier otro fármaco biológico directamente dirigido contra la interleuquina (IL)-17 o el receptor de IL-17.
5. Uso de otros fármacos en investigación en el momento de la inclusión o en un periodo de 5 semividas o de 30 días, aquel periodo que sea más largo, previos al inicio del tratamiento en investigación hasta que el efecto farmacodinámico previsto vuelva a los valores basales, o durante más tiempo si así lo exige la normativa local.
6. Mujeres embarazadas o en periodo de lactancia, donde embarazo se define como el estado de una mujer después de la concepción y hasta que finalice la gestación, confirmado por un resultado positivo en la analítica de gonadotropina coriónica humana (hCG).
7. Antecedentes de enfermedad linfoproliferativa, cualquier tumor maligno o antecedentes de tumor maligno de cualquier sistema orgánico tratado o no tratado durante los 5 años anteriores a la selección, independientemente de que exista evidencia de recurrencia local o metástasis (excepto enfermedad de Bowen, carcinoma de células basales o queratosis actínicas que hayan sido tratadas y sin signos de reaparición durante las últimas 12 semanas; carcinoma de cérvix in situ o pólipos de colon malignos no invasivos que hayan sido extirpados).
8. Antecedentes de hipersensibilidad a cualquier componente del fármaco del estudio.

Para el reto de criterios consultar protocolo.

E.5 End points

E.5.1

Primary end point(s)

PASI 75 response and IGA mod 2011 0 or 1 response

Respuesta PASI 75 y respuesta IGA mod 2011 0 o 1

E.5.1.1

Timepoint(s) of evaluation of this end point

Week 12

Semana 12

E.5.2

Secondary end point(s)

1) PASI 90
2) PASI 50/75/90/100 and IGA mod 2011 0 or 1
3) Vital signs, lab variables, AE
4) SIAQ questionnaire and administration observation
5) DLQI 0 or 1

1) PASI 90
2) PASI 50/75/90/100 e IGA mod 2011 0 o 1
3) Signos vitales, variables de laboratorio, AE
4) Cuestionario SIAQ y observación de la administración
5) DLQI 0 o 1

E.5.2.1

Timepoint(s) of evaluation of this end point

- At Week 12: 1); 2); 5)
- Over time up to Week 52: 2); 3); 4); 5)

-En la semana 12: 1); 2); 5)
-Con el tiempo hasta la semana 52: 2); 3); 4); 5)

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

E.6.3

Therapy

Yes

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

Yes

E.6.7

Pharmacodynamic

Yes

E.6.8

Bioequivalence

E.6.9

Dose response

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

E.7.3

Therapeutic confirmatory (Phase III)

Yes

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

E.8.1.3

Single blind

E.8.1.4

Double blind

Yes

E.8.1.5

Parallel group

Yes

E.8.1.6

Cross over

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

E.8.2.2

Placebo

Yes

E.8.2.3

Other

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

Yes

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.6.3

If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned

Canada

Germany

Iceland

Poland

Spain

United States

E.8.7

Trial has a data monitoring committee

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

LVLS

Último paciente, última visita

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

E.8.9.2

In all countries concerned by the trial months

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

F.1.2

Adults (18-64 years)

Yes

F.1.2.1

Number of subjects for this age range:

110

F.1.3

Elderly (>=65 years)

Yes

F.1.3.1

Number of subjects for this age range:

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

Yes

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

F.4.2

For a multinational trial

F.4.2.1

In the EEA

F.4.2.2

In the whole clinical trial

120

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

When subject leaves the study, the investigator will discuss the different medications or possible alternatives that are available to treat the subject's psoriasis

Cuando el paciente abandone el estudio, el investigador analizará los diferentes medicamentos o las posibles alternativas disponibles para tratar la psoriasis del paciente.

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2019-03-12

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2019-03-06

P. End of Trial
P.	End of Trial Status	Completed
P.	Date of the global end of the trial	2020-08-05

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials